Modified-Release Oral Minoxidil for Stable Serum Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short-lived serum concentrations, leading to adverse effects and inefficiencies in hair regrowth promotion.
Innovation Solution
A modified release formulation of minoxidil or its pharmaceutically acceptable salts, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, achieving a Tmax of 30 to 360 minutes and a Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained serum levels for effective hair regrowth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical minoxidil is administered, then hair regrowth is promoted, but rapid absorption occurs leading to short-lived serum concentrations and adverse effects
Solution Approach 1:
The patent applies dynamics by transitioning from static topical application to dynamic controlled-release oral delivery. The modified release formulation dynamically adjusts drug release rates to maintain optimal serum concentrations, preventing both rapid spikes (causing adverse effects) and premature drops (reducing efficacy). This dynamic control resolves the contradiction between maintaining therapeutic levels and avoiding toxicity.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of minoxidil delivery by using modified release formulations with specific release rates (50-90% over 12-24 hours). This parameter change transforms the absorption profile from rapid and short-lived to sustained and controlled, thereby maintaining therapeutic serum concentrations while reducing adverse effects associated with peak concentrations.
2Speed
If topical minoxidil is applied, then serum concentrations are achieved quickly, but the concentrations are short-lived requiring frequent application
Solution Approach 1:
The patent applies periodic action through modified release formulations that release minoxidil in controlled periods (50-90% over 12-24 hours). This creates a sustained periodic delivery system that maintains serum concentrations throughout the dosing interval, eliminating the need for frequent reapplication while ensuring continuous therapeutic effect.
Solution Approach 2:
The patent achieves continuity of useful action by designing formulations that maintain minoxidil serum concentrations continuously over extended periods. The modified release mechanism ensures uninterrupted drug availability in the bloodstream, transforming the discontinuous short-lived concentrations of topical application into continuous therapeutic levels.
3Productivity
If immediate release formulation is used, then rapid therapeutic effect is achieved, but adverse effects increase due to high peak concentrations
Solution Approach 1:
The patent uses dynamics to control the rate and pattern of drug release, transforming the abrupt peak-concentration profile of immediate release formulations into a dynamic, controlled-release profile. This dynamic delivery maintains therapeutic efficacy while avoiding the harmful peak concentrations that cause adverse effects.
Solution Approach 2:
The patent changes the release rate parameter of minoxidil from immediate to modified release (50-90% over 12-24 hours). This parameter change fundamentally alters the concentration-time profile, reducing peak concentrations that cause adverse effects while maintaining the productivity of rapid therapeutic response through optimized release kinetics.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.